新诊断的异柠檬酸脱氢酶野生型胶质母细胞瘤与颞肌厚度：一项多中心分析。
Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis.
作者信息
Wende Tim, Kasper Johannes, Prasse Gordian, Glass Änne, Kriesen Thomas, Freiman Thomas M, Meixensberger Jürgen, Henker Christian
机构信息
Department of Neurosurgery, University Hospital Leipzig, 04103 Leipzig, Germany.
Department of Neuroradiology, University Hospital Leipzig, 04103 Leipzig, Germany.
出版信息
Cancers (Basel). 2021 Nov 10;13(22):5610. doi: 10.3390/cancers13225610.
BACKGROUND
Reduced temporal muscle thickness (TMT) has been discussed as a prognostic marker in IDH-wildtype glioblastoma. This retrospective multicenter study was designed to investigate whether TMT is an independent prognostic marker in newly diagnosed glioblastoma.
METHODS
TMT was retrospectively measured in 335 patients with newly diagnosed glioblastoma between 1 January 2014 and 31 December 2019 at the University Hospitals of Leipzig and Rostock. The cohort was dichotomized by TMT and tested for association with overall survival (OS) after 12 months by multivariate proportional hazard calculation.
RESULTS
TMT of 7.0 mm or more was associated with increased OS (46.3 ± 3.9% versus 36.6 ± 3.9%, > 0.001). However, the sub-groups showed significant epidemiological differences. In multivariate proportional hazard calculation, patient age (HR 1.01; = 0.004), MGMT promoter status (HR 0.76; = 0.002), EOR (HR 0.61), adjuvant irradiation (HR 0.24) and adjuvant chemotherapy (HR 0.40; all < 0.001) were independent prognostic markers for OS. However, KPS (HR 1.00, = 0.31), BMI (HR 0.98, = 0.11) and TMT (HR 1.06; = 0.07) were not significantly associated with OS.
CONCLUSION
TMT has not appeared as a statistically independent prognostic marker in this cohort of patients with newly diagnosed IDH-wildtype glioblastoma.
背景
颞肌厚度（TMT）降低已被讨论作为异柠檬酸脱氢酶（IDH）野生型胶质母细胞瘤的预后标志物。这项回顾性多中心研究旨在调查TMT是否为新诊断胶质母细胞瘤的独立预后标志物。
方法
回顾性测量了2014年1月1日至2019年12月31日期间在莱比锡和罗斯托克大学医院新诊断的335例胶质母细胞瘤患者的TMT。该队列根据TMT进行二分法，并通过多变量比例风险计算测试与12个月后总生存期（OS）的相关性。
结果
TMT为7.0mm或更高与OS增加相关（46.3±3.9%对36.6±3.9%，P>0.001）。然而，亚组显示出显著的流行病学差异。在多变量比例风险计算中，患者年龄（HR 1.01；P=0.004）、O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子状态（HR 0.76；P=0.002）、切除程度（EOR）（HR 0.61）、辅助放疗（HR 0.24）和辅助化疗（HR 0.40；均P<0.001）是OS的独立预后标志物。然而， Karnofsky功能状态评分（KPS）（HR 1.00，P=0.31）、体重指数（BMI）（HR 0.98，P=0.11）和TMT（HR 1.06；P=0.07）与OS无显著相关性。
结论
在这个新诊断的IDH野生型胶质母细胞瘤患者队列中，TMT未表现为统计学上独立的预后标志物。
Zotero 插件